Home » Spectrum Terminates Ozarelix Development Program in BPH
Spectrum Terminates Ozarelix Development Program in BPH
Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary
focus in oncology, Wednesday announced that it is discontinuing development of ozarelix in benign prostatic hypertrophy (BPH).
GEN
GEN
Upcoming Events
-
07May
-
14May
-
30May